No abstract available
MeSH terms
-
Adolescent
-
Antineoplastic Agents / adverse effects*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Benzamides
-
Bone Marrow Transplantation
-
Camptothecin / administration & dosage
-
Camptothecin / analogs & derivatives*
-
Child
-
Combined Modality Therapy
-
Edema / etiology
-
Enzyme Inhibitors / adverse effects*
-
Etoposide / therapeutic use
-
Female
-
Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use
-
Hematopoietic Stem Cell Transplantation
-
Humans
-
Imatinib Mesylate
-
Irinotecan
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy
-
Leukemic Infiltration / drug therapy
-
Lung Neoplasms / secondary
-
Lung Neoplasms / therapy
-
Male
-
Neoplasm Proteins / antagonists & inhibitors
-
Neuroectodermal Tumors, Primitive / secondary
-
Neuroectodermal Tumors, Primitive / therapy
-
Piperazines / adverse effects*
-
Pleural Effusion / chemically induced*
-
Proto-Oncogene Proteins c-kit / drug effects
-
Pyrimidines / adverse effects*
-
Remission Induction
-
Sarcoma, Ewing / secondary
-
Sarcoma, Ewing / therapy
-
Testis / pathology
-
Topotecan / administration & dosage
Substances
-
Antineoplastic Agents
-
Benzamides
-
Enzyme Inhibitors
-
Neoplasm Proteins
-
Piperazines
-
Pyrimidines
-
Etoposide
-
Irinotecan
-
Topotecan
-
Granulocyte-Macrophage Colony-Stimulating Factor
-
Imatinib Mesylate
-
Proto-Oncogene Proteins c-kit
-
Camptothecin